Niagen Bioscience, Inc. (NAGE) Q2 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Niagen Bioscience, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:01.297 -- 00:00:05.944 Ladies and gentlemen, thank you for standing by and welcome to Niagen Biosciences Inc's 00:00:05.944 -- 00:00:09.009 second quarter of 2025 earnings conference call. 00:00:09.009 -- 00:00:12.154 My name is JL and I will be your conference operator today. 00:00:12.154 -- 00:00:15.939 At this time all participants are in a listen-only mode and as a reminder this conference 00:00:15.939 -- 00:00:20.586 call is being recorded. This afternoon Niagen Biosciences 00:00:20.586 -- 00:00:24.072 issued a news release announcing the company's financial results for the second quarter 00:00:24.072 -- 00:00:29.206 of 2025. If you have not reviewed this information, Both are available within 00:00:29.206 -- 00:00:34.690 the investor relations section of Niogen Bioscience's website at www.niogenbioscience.com. 00:00:38.096 -- 00:00:42.742 I would now like to turn the conference call over to Kendall, Senior Director of Publicity 00:00:42.742 -- 00:00:46.484 and Public Relations. Please go ahead. 00:00:51.011 -- 00:00:55.229 Thank you. Good afternoon, and welcome to Niogen Bioscience, Inc. 00:00:55.229 -- 00:01:00.316 second quarter of 2025 conference call. With us today are Niagen 00:01:00.316 -- 00:01:05.423 Biosciences Chief Executive Officer Rob Fried, Chief Financial 00:01:05.423 -- 00:01:10.711 Officer Ozan Pamir, and Senior Vice President of Scientific and Regulatory 00:01:10.711 -- 00:01:13.535 Affairs, Dr. Andrew Hsiao. 00:01:13.535 -- 00:01:17.477 Dr. Hsiao will join the call for Q&A. 00:01:17.858 -- 00:01:22.384 Today's conference call may include forward-looking statements, including statements 00:01:22.384 -- 00:01:27.351 related to the company's research and development and clinical trial plans and the timing 00:01:27.351 -- 00:01:32.77...